NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019.
Publication
, Journal Article
Wierda, WG; Byrd, JC; Abramson, JS; Bilgrami, SF; Bociek, G; Brander, D; Brown, J; Chanan-Khan, AA; Chavez, JC; Coutre, SE; Davis, RS; Hill, B ...
Published in: J Natl Compr Canc Netw
January 2019
Chronic lymphocytic leukemia (CLL) is generally characterized by an indolent disease course. Histologic transformation (also known as Richter's transformation) to more aggressive lymphomas, such as diffuse large B-cell lymphoma or Hodgkin lymphoma, occurs in approximately 2% to 10% of patients and is associated with a poor prognosis. These NCCN Guidelines Insights discuss the recommendations for the diagnosis and management of patients with histologic transformation.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
January 2019
Volume
17
Issue
1
Start / End Page
12 / 20
Location
United States
Related Subject Headings
- United States
- Societies, Medical
- Progression-Free Survival
- Oncology & Carcinogenesis
- Medical Oncology
- Leukemia, Lymphocytic, Chronic, B-Cell
- Humans
- Clinical Trials as Topic
- Antineoplastic Combined Chemotherapy Protocols
- 4203 Health services and systems
Citation
APA
Chicago
ICMJE
MLA
NLM
Wierda, W. G., Byrd, J. C., Abramson, J. S., Bilgrami, S. F., Bociek, G., Brander, D., … Sundar, H. (2019). NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. J Natl Compr Canc Netw, 17(1), 12–20. https://doi.org/10.6004/jnccn.2019.0002
Wierda, William G., John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, et al. “NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019.” J Natl Compr Canc Netw 17, no. 1 (January 2019): 12–20. https://doi.org/10.6004/jnccn.2019.0002.
Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, et al. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. J Natl Compr Canc Netw. 2019 Jan;17(1):12–20.
Wierda, William G., et al. “NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019.” J Natl Compr Canc Netw, vol. 17, no. 1, Jan. 2019, pp. 12–20. Pubmed, doi:10.6004/jnccn.2019.0002.
Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Malek S, Mato A, Mosse C, Neppalli VT, Shadman M, Siddiqi T, Stephens D, Wagner N, Dwyer MA, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. J Natl Compr Canc Netw. 2019 Jan;17(1):12–20.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
January 2019
Volume
17
Issue
1
Start / End Page
12 / 20
Location
United States
Related Subject Headings
- United States
- Societies, Medical
- Progression-Free Survival
- Oncology & Carcinogenesis
- Medical Oncology
- Leukemia, Lymphocytic, Chronic, B-Cell
- Humans
- Clinical Trials as Topic
- Antineoplastic Combined Chemotherapy Protocols
- 4203 Health services and systems